Tweet
Posted by John Keller
Evidently the U.S. government is taking the threat of a global bird flu pandemic very seriously, as the U.S. Department of Health and Human Services (HHS) has awarded five contracts collectively worth as much as $25.36 billion for medical countermeasures to the H5N1 avian influenza virus.
There is ample reason to take the threat of an H5N1 bird flu pandemic seriously, too. Over the last decade there have been 608 confirmed cases of H5N1 in humans, according to the World Health Organization (WHO) in Geneva. Of those, 359 died; that's nearly a 70 percent mortality rate.
Of those confirmed cases of H5N1 and their resulting deaths, most have been in Indonesia, Vietnam, and Egypt. No cases have been reported in the U.S. -- yet.
To keep any potential H5N1 bird flu pandemic in check, HHS officials on 4 Sept. awarded contracts potentially worth $9 billion to Novartis Vaccines and Diagonostics Inc. in Boston; $8.2 billion to MedImmune LLC in Gaithersburg, Md.; $4.7 billion to Sanofi Pasteur Inc. in Swiftwater, Pa.; $2 billion to GlaxoSmithKline LLC in Philadelphia; and $1.5 billion to CSL Biotherapies Inc. in King of Prussia, Pa.
...
Evidently the U.S. government is taking the threat of a global bird flu pandemic very seriously, as the U.S. Department of Health and Human Services (HHS) has awarded five contracts collectively worth as much as $25.36 billion for medical countermeasures to the H5N1 avian influenza virus.
There is ample reason to take the threat of an H5N1 bird flu pandemic seriously, too. Over the last decade there have been 608 confirmed cases of H5N1 in humans, according to the World Health Organization (WHO) in Geneva. Of those, 359 died; that's nearly a 70 percent mortality rate.
Of those confirmed cases of H5N1 and their resulting deaths, most have been in Indonesia, Vietnam, and Egypt. No cases have been reported in the U.S. -- yet.
To keep any potential H5N1 bird flu pandemic in check, HHS officials on 4 Sept. awarded contracts potentially worth $9 billion to Novartis Vaccines and Diagonostics Inc. in Boston; $8.2 billion to MedImmune LLC in Gaithersburg, Md.; $4.7 billion to Sanofi Pasteur Inc. in Swiftwater, Pa.; $2 billion to GlaxoSmithKline LLC in Philadelphia; and $1.5 billion to CSL Biotherapies Inc. in King of Prussia, Pa.
...
